ANTIBODY DEPLETION AND CYTOTOXIC DRUG-THERAPY IN SEVERE SYSTEMIC LUPUS-ERYTHEMATOSUS

被引:38
作者
EULER, HH
SCHROEDER, JO
机构
[1] 2nd Medical Clinic, Christian-Albrechts University, D-2300 Kiel
来源
TRANSFUSION SCIENCE | 1992年 / 13卷 / 02期
关键词
D O I
10.1016/0955-3886(92)90167-F
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The established treatment of severe systemic lupus erythematosus (SLE) includes corticosteroids and cytotoxic drugs. Therapeutic plasmapheresis may provide additional rapid relief, but this is only temporary. Controlled trials have repeatedly demonstrated that long-term improvement cannot be achieved if plasmaphereses are performed in addition to long-term oral immunosuppression, as is the usual procedure. This might be an indication that the organism has a considerable ability to re-establish the status quo ante. By contrast, uncontrolled case reports indicate that both rapid and long-term benefits may be achieved by combining plasmapheresis with subsequent pulses of an alkylating agent. The approach used in these studies theorizes that antibody depletion induces increased proliferation of pathogenic clones and that it should be possible to exploit this increased proliferation for the enhanced deletion of pathogenic clones by the subsequent application of pulse cyclophosphamide. The present paper reviews the literature and summarizes the results achieved with the treatment of severe SLE using cytotoxic agents and antibody elimination. Additionally, the authors discuss how the organism's ability to achieve rapid counterregulation might be utilized to improve the therapeutic results, and they attempt to develop perspectives for the future.
引用
收藏
页码:167 / 184
页数:18
相关论文
共 132 条
  • [1] Klippel, Survival in SLE, Proceedings of the Second International Conference in Systemic Lupus Erythematosus, pp. 187-189, (1990)
  • [2] Reveille, Barolucci, Alarcon-Segovia, Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death, Arthritis Rheum, 33, pp. 37-48, (1990)
  • [3] Austin, Klippel, Balow, LeRiche, Steinberg, Plotz, Decker, Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs, N Engl J Med, 314, pp. 614-619, (1986)
  • [4] Klippel, Systemic lupus erythematosus. Treatment-related complications superimposed on chronic disease, J Am Med Assoc, 263, pp. 1812-1815, (1990)
  • [5] Baker, Kahl, Zee, Stolzer, Agarwal, Medsger, Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. A long-term case-control follow-up study, Am J Med, 83, pp. 1-9, (1987)
  • [6] Cupps, Cyclophosphamide: To pulse or not to puls, Am J Med, 89, pp. 399-402, (1990)
  • [7] Fox, McCune, Immunologic and clinical effects of cytotoxic drugs used in the treatment of rheumatoid arthritis and systemic lupus erythematosus, Therapy of Autoimmune Diseases, pp. 20-78, (1989)
  • [8] Hill, Scott, Cytotoxic drugs for systemic lupus (letter), Br Med J, 1, (1964)
  • [9] Barrat, Soothill, Controlled trial of cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood, Lancet, 2, pp. 479-482, (1970)
  • [10] Steinberg, Kaltreider, Staples, Goetzl, Talal, Decker, Cyclophosphamide in lupus nephritis: a controlled trial, Ann Intern Med, 75, pp. 165-171, (1971)